Sunday, September 13, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 19, 2026

Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus

View original at finance.yahoo.com
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus Last Friday, the three most widely followed benchmark indexes closed a losing week…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The hypothetical equal-weight portfolio of Zacks Rank #1 stocks returned +22.4% in 2024 vs. +13.7% for the equal-weight S&P 500 index

    80% confidence

  • An equal-weight portfolio of Zacks Rank #1 (Strong Buy) stocks outperformed the equal-weight S&P 500 index by 7 percentage points (+17.81% vs. +10.85%)

    80% confidence

  • Investor sentiment was affected by a mix of tariff-related trade war fears and uncertainty about economic policy

    80% confidence

  • Over the 10-year period (2016 through 2025), the portfolio of equal-weight Zacks Rank #1 stocks outperformed the equal-weight S&P 500 index by more than 7 percentage points (+18.55% vs. +11.65%)

    80% confidence

  • Tariff jitters prompted safe-haven flows into gold and pushed markets to price in heightened geopolitical risk

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus — Source | Via News | Finance Via News